Skip to content
2000
Volume 3, Issue 13
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The replication cycle of human immunodeficiency virus (HIV) is divided into an early and a late phase. Most of the steps of the cycle have been targeted in antiviral therapy, although the drugs currently available for clinical use are only effective against two replication enzymes of the virus, either against the reverse transcriptase or against the viral protease. The introduction of combination anti-retroviral therapy changed the prognosis of HIV infection. HIV-related morbidity and mortality rates in patients with advanced HIV infection have significantly declined. However, there are severe limits of HAART. Current anti-retroviral therapy do not allow viral eradication, therefore long-term use of the drugs is required. As a consequence, resistance develops in a significant portion of patients. Furthermore, several adverse metabolic side effects have been observed associated with the therapy. Therefore new approaches are required to control or eradicate this deadly virus infection.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026033451781
2003-09-01
2025-05-07
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026033451781
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test